<DOC>
	<DOCNO>NCT01643603</DOCNO>
	<brief_summary>This study use drug call dasatinib produce anti-cancer effect call large granular lymphocyte cellular expansion . Large granular lymphocyte blood cell know natural killer cell remove cancer cell . Researchers think dasatinib may cause large granular lymphocyte expansion happen patient receive blood stem cell transplant ( SCT ) 3 15 month SCT . In research study , researcher want find well dasatinib tolerate , best dose take dasatinib estimate often large granular lymphocytic cellular expansion happen best dose dasatinib .</brief_summary>
	<brief_title>Dasatinib Immune Modulation After Donor Stem Cell Transplant Hematologic Malignancies</brief_title>
	<detailed_description>This phase I , dose-escalation study follow phase II study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Recipients first ASCT relate unrelated donor treatment hematologic malignancy ( acute myeloid leukemia , chronic myeloid leukemia , acute lymphoblastic leukemia , chronic lymphocytic leukemia , myelodysplastic syndrome , Hodgkin nonHodgkin lymphoma ) 1antigen 1allele mismatch fully match human leukocyte antigen ( HLA ) A , B , C DR define high resolution type Patients must 100 180 day allogeneic stem cell transplantation Dasatinib use prior ASCT allow Performance status &gt; = 60 % Presence large granular lymphocyte ( LGL ) clone prior enrollment exclusion criterion LGL clone &lt; 25 % T cell population Total bilirubin &lt; 2.0 time institutional upper limit normal ( ULN ) Hepatic enzyme ( aspartate aminotransferase [ AST ] , alanine aminotransferase [ ALT ] ) = &lt; 2.5 time institutional ULN Serum creatinine &lt; 1.5 time institutional ULN Hemoglobin &gt; = 8 g/dL Absolute neutrophil count 1,500 cell per uL Platelets &gt; = 100,000 per uL Patient able provide sign write informed consent : Before study procedure perform , subject detail study describe , give write informed consent document read ; , subject consent participate study , indicate consent sign date informed consent document presence study personnel Written consent include Health Insurance Portability Accountability Act ( HIPAA ) form accord institutional guideline Patient able take oral medication ( dasatinib must swallow whole ) Recipient mismatch ( allele antigen level ) graft one locus HLAA , B , C DR locus eligible , i.e . recipient 2antigen 2allelele mismatch graft Patients investigational therapy graftversushost disease ( GVHD ) Patients uncontrolled acute chronic GVHD refractory disease respond conventional therapy Patients evidence disease progression day 100 ASCT Women childbearing potential ( WOCBP ) unwilling unable use acceptable method avoid pregnancy entire study period least 4 week last dose study drug Women pregnant breastfeed Women positive pregnancy test Sexually active fertile men use effective birth control partner WOCBP No malignancy [ one treat study ] require radiotherapy systemic treatment within past 5 year Concurrent medical condition may increase risk toxicity , include : Pleural pericardial effusion grade time screen study Cardiac Symptoms ; follow consider exclusion : Uncontrolled angina , congestive heart failure myocardial infarction ( MI ) within ( 6 month ) Diagnosed congenital long QT syndrome Any history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , Torsades de pointes ) Prolonged QTc interval preentry electrocardiogram ( &gt; 450 msec ) History significant bleeding disorder unrelated cancer , include : Diagnosed congenital bleeding disorder ( e.g. , von Willebrand 's disease ) Diagnosed acquire bleed disorder within one year ( e.g. , acquire antifactor VIII antibody ) Ongoing recent ( = &lt; 3 month ) significant gastrointestinal bleeding Any previous history &gt; = grade 3 toxicity Dasatinib Prohibited treatment therapy : Category I drug generally accept risk cause Torsades de Pointes include : ( Patients must discontinue drug 7 day prior start dasatinib ) Quinidine , procainamide , disopyramide Amiodarone , sotalol , ibutilide , dofetilide Erythromycin , clarithromycin Chlorpromazine , haloperidol , mesoridazine , thioridazine , pimozide Cisapride , bepridil , droperidol , methadone , arsenic , chloroquine , Domperidone , halofantrine , levomethadyl , pentamidine , sparfloxacin , lidoflazine Patient agree discontinue St. Johns Wort receive dasatinib therapy ( discontinue St. Johns Wort least 5 day start dasatinib ) Patient agree IV bisphosphonates withhold first 8 week dasatinib therapy due risk hypocalcemia Prisoners subject involuntarily incarcerate Subjects compulsorily detain treatment either psychiatric physical ( egg , infectious disease ) illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia del ( 5q )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>cutaneous B-cell non-Hodgkin lymphoma</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>hepatosplenic T-cell lymphoma</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncutaneous extranodal lymphoma</keyword>
	<keyword>peripheral T-cell lymphoma</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult lymphoblastic lymphoma</keyword>
	<keyword>stage I adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage IA mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IB mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IIA mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IIB mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IIIA mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IIIB mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IVA mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IVB mycosis fungoides/Sezary syndrome</keyword>
	<keyword>T-cell large granular lymphocyte leukemia</keyword>
	<keyword>testicular lymphoma</keyword>
	<keyword>Waldenstr√∂m macroglobulinemia</keyword>
</DOC>